Sign in

Gene Mack

Chief Executive Officer at Gain Therapeutics
Board
Since January 6, 2025
Age
51 years
Education
Earned a BS in Biochemistry and an MBA in Finance from Fordham University.
Tenure
Joined GANX as CFO on April 8, 2024, was elevated to Interim CEO on June 25, 2024, and began serving as Chief Executive Officer on January 6, 2025.

Also at Gain Therapeutics

GF
Gianluca Fuggetta
Senior Vice President Finance and Principal Financial Officer

About

Gene Mack has built an extensive career in the biotechnology and pharmaceutical industries, serving in senior financial roles and contributing significantly to strategic financial operations.

At GANX, he began his tenure as CFO on April 8, 2024, swiftly transitioning to Interim CEO on June 25, 2024, and ultimately assuming the role of Chief Executive Officer on January 6, 2025, demonstrating a clear trajectory of leadership and advancement.

With a solid educational foundation from Fordham University—holding a BS in Biochemistry and an MBA in Finance—his expertise in managing corporate finance and strategic initiatives positions him as a key contributor to the company’s ongoing growth.

$GANX Performance Under Gene Mack

Past Roles

OrganizationRoleDate RangeDetails
Gain Therapeutics, Inc. (GANX) Interim Chief Executive Officer June 25, 2024 – January 6, 2025 Held the role concurrently with CFO until his appointment as permanent CEO
Gain Therapeutics, Inc. (GANX) Chief Financial Officer April 8, 2024 – January 6, 2025 Transitioned from CFO upon becoming permanent CEO
Imcyse SA Chief Financial Officer October 2021 – October 2023 Biotechnology firm developing novel immunotherapeutics
OncoC4, Inc. Chief Financial Officer September 2020 – September 2021 Company spun out after a $475M acquisition by Merck & Co.
BiomUp, USA Inc. Chief Financial Officer May 2019 – September 2020 Focused on the development of novel hemostatic agents for surgery
Sellas Lifesciences Group, Inc. (Nasdaq: SLS) Chief Financial Officer April 2018 – December 2018 Served during the reverse merger with Galena Biopharma
Ascendia Pharmaceuticals and Nicox S.A. Consultant and Senior Vice President, Chief Financial Officer 2015 – March 2018 Provided advisory services for capital raising and business development
Edge Therapeutics Senior Director, Corporate Finance 2013 – 2015 Led the company's successful IPO efforts
Various Banking Institutions Senior Publishing Analyst 2000 – 2013 Covered the life sciences sector at firms including Gruntal & Co., Lazard, and HSBC
Cornell University Medical College and Columbia University College of Physicians and Surgeons Researcher N/A Conducted research in biochemistry and clinical neurology (non-academic role)

Fixed Compensation

Data from  FY 2025
Component NameAmountPayment ScheduleAdditional Details
Annual Base Salary$500,000 AnnualEffective January 6, 2025 under the amended employment agreement for the permanent CEO appointment

Performance Compensation

Data from  FY 2025

Annual Incentive Cash Bonus

MetricValueNotes
Target Bonus Percentage50% Discretionary cash bonus based on individual and company performance
Base Salary for Calculation$500,000 Used to compute the bonus target
Target Bonus Amount$250,000 Calculated as 50% of the annual base salary
Performance MetricsN/ASpecific performance metrics, thresholds, and goals not provided
Vesting ScheduleN/ANot applicable for this cash bonus
Evaluation PeriodN/ADetails not provided
Additional ConditionsDiscretionary payout determined by the Compensation CommitteeBased on overall evaluation of performance